Recent Insider Transactions Derivative • Jun 16
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of June. If the sale is conducted around the recent share price of US$20.81, it would amount to US$312k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Brian's direct individual holding has decreased from 309.34k shares to 246.55k. There has only been one transaction (US$200k purchase) from insiders over the last 12 months. Recent Insider Transactions Derivative • May 17
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of May. If the sale is conducted around the recent share price of US$20.96, it would amount to US$314k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Brian's direct individual holding has decreased from 309.34k shares to 261.55k. There has only been one transaction (US$200k purchase) from insiders over the last 12 months. Announcement • Apr 24
Kestra Medical Technologies Ltd Exhibits Cardiac Recovery System Platform at Heart Rhythm 2026 Kestra Medical Technologies, Ltd. announced it will exhibit at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society (HRS) taking place April 23–26 in Chicago. The company will showcase its Cardiac Recovery System platform—a modern, integrated approach to managing sudden cardiac arrest (SCA) risk that unites proven therapy, actionable clinical insights, and ongoing patient support to enhance protection and optimize care. Kestra continues to build momentum as clinicians increasingly shift toward more connected approaches to SCA risk management. At HRS, attendees will see why more clinicians are turning to Kestra to improve patient protection and better manage risk during the most vulnerable stages of recovery. The ASSURE WCD is at the center of the Cardiac Recovery System platform. Insights from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS)—the prospective study of wearable defibrillators to date—demonstrate robust real-world performance and continue to guide innovation across the platform. At HRS, Kestra is launching a recently FDA-approved ASSURE WCD algorithm update that builds on market-leading clinical performance and applies real-world data to further enhance patient protection and advance care. Kestra will be located at Booth 2119, where attendees can experience the ASSURE system firsthand, explore the Cardiac Recovery System platform through an immersive multimedia experience, and review clinical data from ACE-PAS. Recent Insider Transactions Derivative • Apr 16
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of April. If the sale is conducted around the recent share price of US$20.04, it would amount to US$301k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Brian's direct individual holding has decreased from 309.34k shares to 276.55k. There has only been one transaction (US$200k purchase) from insiders over the last 12 months. Recent Insider Transactions Derivative • Mar 19
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$20.27, it would amount to US$304k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Brian's direct individual holding has decreased from 309.34k shares to 291.55k. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Reported Earnings • Mar 19
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: US$0.61 loss per share. Revenue: US$24.6m (up 63% from 3Q 2025). Net loss: US$34.2m (loss widened 38% from 3Q 2025). Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) missed analyst estimates by 2.4%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Announcement • Mar 18
Kestra Medical Technologies, Ltd. Raises Earnings Guidance for the Fiscal Year 2026 Kestra Medical Technologies, Ltd. raised earnings guidance for the Fiscal Year 2026. For the period, the company expects revenue to be $93 million, which would represent growth of 55% compared to FY25. This compares to prior FY26 revenue guidance of $91 million and initial FY26 guidance of $85 million. Announcement • Mar 03
Kestra Medical Technologies, Ltd. to Report Q3, 2026 Results on Mar 17, 2026 Kestra Medical Technologies, Ltd. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Mar 17, 2026 Recent Insider Transactions Derivative • Feb 18
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of February. If the sale is conducted around the recent share price of US$25.60, it would amount to US$384k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Brian's direct individual holding has decreased from 309.34k shares to 306.55k. There has only been one transaction (US$289k purchase) from insiders over the last 12 months. Recent Insider Transactions Derivative • Jan 16
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of January. If the sale is conducted around the recent share price of US$22.80, it would amount to US$342k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Brian's direct individual holding has increased from 309.34k shares to 321.55k. There has only been one transaction (US$289k purchase) from insiders over the last 12 months. Recent Insider Transactions Derivative • Dec 31
Founder notifies of intention to sell stock Brian Webster intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of December. If the sale is conducted around the recent share price of US$26.59, it would amount to US$399k. For the year to April 2024, Brian's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Brian has owned 309.34k shares directly. There has only been one transaction (US$289k purchase) from insiders over the last 12 months. Reported Earnings • Dec 12
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: US$0.64 loss per share. Revenue: US$22.6m (up 53% from 2Q 2025). Net loss: US$32.8m (loss widened 38% from 2Q 2025). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) missed analyst estimates by 8.2%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Announcement • Dec 12
Kestra Medical Technologies, Ltd. Revises Earnings Guidance for the Fiscal Year 2026 Kestra Medical Technologies, Ltd. revised earnings guidance for the fiscal year 2026. For the year, Kestra is increasing its revenue guidance to $91 million, which would represent growth of 52% compared to FY25. This compares to prior Fiscal Year 2026 revenue guidance of $88 million and initial FY26 guidance of $85 million. Announcement • Nov 11
Kestra Medical Technologies, Ltd. Announces Primary Results from the Assure®? WCD Clinical Evaluation Post-Approval Study Kestra Medical Technologies, Ltd. announced primary results from the ASSURE®? WCD Clinical Evaluation Post-Approval Study (ACE-PAS), presented as a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. ACE-PAS, the largest prospective real-world study of wearable defibrillators to date, confirmed the strong safety and effectiveness of the ASSURE WCD in clinical practice. The study enrolled 21,612 patients across the United States. Key findings demonstrate consistent safety, effectiveness, and compliance in real-world use: Proven effectiveness: The primary effectiveness endpoint was achieved, with 100% successful conversion for ventricular tachycardia and fibrillation (VT/VF) events, surpassing the prespecified performance goal; Validated safety: The study met its primary safety endpoint, with an inappropriate-shock rate of 0.0065 per patient-month, below the prespecified performance goal and confirming a strong safety profile; Minimal false alarms; 94% of patients experienced no false positive shock alarms, ensuring confidence and comfort during wear; Critical protection; 2.6% of patients experienced at least one life-threatening VT/VF event within only a few months, highlighting the importance of protection in this vulnerable population; Additional clinically relevant arrhythmias revealed; The ASSURE system facilitated detection of high-rate atrial fibrillation in 4.2% of patients (35% previously undiagnosed) and severe bradycardia/asystole in 0.3%, enabling the potential of timely intervention; High compliance; Patients wore the device for a median of more than 23 hours per day, and one-third continued use beyond 90 days--highlighting its practicality in real-world, long-term care. The ASSURE WCD Clinical Evaluation Post- Approval Study (ACE- PAS) is a prospective, multicenter registry evaluating the use, safety, and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in the prevention of sudden cardiac death. The study enrolled 21,12 patients from November 2021 through July 2025 across the U.S. Primary endpoints were overall VT/VF shock conversion and inappropriate-shock rate. Announcement • Nov 05
Kestra Medical Technologies to Present Late-Breaking Ace-Pas Trial Results At Aha 2025, Showcasing Next-Generation Wearable Defibrillator System Kestra Medical Technologies, Ltd. announced its participation in the American Heart Association (AHA) Scientific Sessions 2025, to be held November 7-10 in New Orleans. Kestra's participation will include a late-breaking science presentation titled Primary Results from the Post-Approval Study of a Next Generation Wearable Cardioverter Defibrillator System (ACE-PAS Trial), scheduled for November 10 at 8:44 a.m. CT in Session 211-213. The ASSURE®? WCD Clinical Evaluation Post-Approval Study (ACE-PAS) is a contemporary study designed to evaluate real-world experience with a next-generation wearable cardioverter defibrillator system. Enrolling more than 20,000 patients across the U.S., ACE-PAS represents the largest prospective WCD study conducted to date. Primary endpoints include overall shock conversion success and inappropriate shock rate, with additional measures evaluating first shock conversion success, median daily wear time, and false alarm rate. The study's selection for AHA's late-breaking science program underscores how wearable defibrillator therapy, and data-driven insights, are advancing the way clinicians approach cardiac recovery and risk protection. At booth #4617, attendees can explore the Kestra Cardiac Recovery System®?, anchored by the ASSURE®? Wearable CardioverterDefibrillator, uniting proven patient protection with the clinical insights providers need to optimize guideline-directed medical therapy, implantable cardioverter defibrillators evaluation, and long-term recovery. In addition to the late-breaking presentation, Kestra will host live demonstrations and discussions throughout the meeting, featuring an immersive in-booth experience that highlights the company's leadership in advancing connected, data-driven solutions for cardiac recovery. Announcement • Oct 07
Kestra Medical Technologies, Ltd. Appoints Timothy Moran as Chief Business Officer, Effective November 3, 2025 Kestra Medical Technologies, Ltd. October 7, 2025, announced the appointment of Timothy Moran as Chief Business Officer, effective November 3, 2025. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. Mr. Moran is a seasoned operating executive who brings over 25 years of experience in medtech organizations to his new role at Kestra. Most recently, he served as President and Chief Executive Officer at Avertix Medical where he led the launch of a first-to-market implantable cardiac device for the detection of acute coronary syndrome events. Prior to that, he was the Chief Executive Officer of Motus GI Holdings. Announcement • Sep 26
Kestra Showcases Cardiac Recovery System Platform At Hfsa 2025, Redefining Sudden Cardiac Arrest Risk Management Kestra Medical Technologies, Ltd. announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26-29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System®? (CRS) platform, anchored by the ASSURE®? Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient-provider connections, and supports recovery for vulnerable patients. Kestra will also participate in the Devices in Heart Failure Meeting on September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guidance-directed medical therapy. New Risk • Sep 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$58m net loss in 3 years). Share price has been volatile over the past 3 months (9.9% average weekly change). Reported Earnings • Sep 12
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: US$0.50 loss per share. Revenue: US$19.4m (up 52% from 1Q 2025). Net loss: US$25.8m (loss widened 16% from 1Q 2025). Revenue exceeded analyst estimates by 8.4%. Earnings per share (EPS) also surpassed analyst estimates by 45%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Announcement • Sep 12
Kestra Medical Technologies, Ltd. Raises Revenue Guidance for the Fiscal Year 2026 Kestra Medical Technologies, Ltd. raised revenue guidance for the fiscal year 2026. For the year, the company now expects revenue of $88 million, representing growth of 47% compared to financial year 2025. This compares to prior revenue guidance of $85 million. Announcement • Aug 28
Kestra Medical Technologies, Ltd. to Report Q1, 2026 Results on Sep 11, 2025 Kestra Medical Technologies, Ltd. announced that they will report Q1, 2026 results on Sep 11, 2025 Announcement • Jul 24
Kestra Medical Technologies, Ltd., Annual General Meeting, Sep 03, 2025 Kestra Medical Technologies, Ltd., Annual General Meeting, Sep 03, 2025. Reported Earnings • Jul 17
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: US$5.13 loss per share. Revenue: US$59.8m (up 115% from FY 2024). Net loss: US$126.1m (loss widened 25% from FY 2024). Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates by 90%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Announcement • Jul 16
Kestra Medical Technologies, Ltd. Provides Revenue Guidance for the Fiscal Year 2026 Kestra Medical Technologies, Ltd. provided revenue guidance for the Fiscal Year 2026. For the year, the company expects revenue of $85 million, an increase of 42% compared to FY25. Announcement • Jun 05
Kestra Medical Technologies Appoints Conor Hanley as Independent Director Effective June 4, 2025 Kestra Medical Technologies, Ltd. announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. Mr. Hanley, 56, currently serves as the Chief Executive Officer of Foundry Innovation & Research 1, Ltd. (“FIRE1”). Mr. Hanley is a strong leader who has served as an integral part of FIRE1’s leadership team for nearly a decade. Mr. Hanley previously worked with ResMed Inc. (“ResMed”) where he held a number of senior management positions including leading up Chronic Disease management solutions globally, the global Cardiology business unit and the Ventures and Initiatives global business unit for corporate investments and accelerating new business. Prior to ResMed, Conor was Chief Executive Officer and Co-Founder of BiancaMed Inc., which was acquired by ResMed in 2011. Over 7 years, he led a team that grew the company through three rounds of venture funding from top-tier international venture funds, launching products in Japan and USA (selling major retailers, including the Apple store) and building the supply chain with mass production in China. Mr. Hanley was awarded a PhD in Chemical Engineering from the University of Pennsylvania, an MBA from INSEAD and a BEng from University College Dublin. Mr. Hanley completed the Leadership4Growth program at Stanford University and is qualified Chartered director from the Institute of Directors, UK. Mr. Hanley will serve as a member of Class I and has not been appointed to serve on any Board committees at this time. Announcement • Apr 30
Kestra Showcases Real-World Outcomes for Assure WCD at Heart Rhythm 2025 Kestra Medical Technologies, Ltd. announced the presentation of new real-world data on the ASSURE®? Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), held April 24-27 in San Diego. The abstract, titled "Real-world Experience with a Novel Wearable CardioverterDefibrillator in a Community setting: Advanced Practice Provider-Driven Care Model," was developed in partnership with Ashley L. Dailey,ANP-BC, MSN and Opesanmi O. Esan, MD, and presented at the annual meeting. The abstract examined outcomes in a nonprofit, community-based medical center using an advanced practice provider (APP)-driven protocol for WCD therapy--one of the first analyses of its kind. The analysis revealed high patient compliance, with a median daily wear time of 23.3 hours and consistent usage, often extending beyond 90 days--highlighting the importance of sustained device use in protecting patients at risk of sudden cardiac death. Notably, ventricular arrhythmias were detected in 4% of patients, even within a predominantly primary prevention population, underscoring the importance of real-time monitoring and early intervention. Among those who received therapy, the outcomes reflect effective continuity of care--with patients benefiting from timely escalation through ICD placement or hospitalization. Additionally, the study highlighted how an APP-driven care model successfully delivered WCD therapy in alignment with guideline-based recommendations--ensuring that all indicated patients received appropriate care and demonstrating the value of structured, team-based approaches in expanding access and improving outcomes within a community-based setting. Announcement • Apr 23
Kestra Medical Technologies, Ltd. to Showcase Innovation in Sudden Cardiac Arrest Protection and Recovery At Heart Rhythm 2025 Kestra Medical Technologies, Ltd. announced it will exhibit at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), taking place April 24-27 at the San Diego Convention Center. This marks Kestra's first major industry showcase following its successful IPO earlier this year. Kestra will debut an immersive in-booth experience designed to bring the ASSURE®? system to life-- demonstrating how this innovative technology is redefining protection for patients at risk of sudden cardiac arrest. By combining lifesaving defibrillation therapy with intuitive, intelligent, and connected diagnostic and patient support capabilities, the ASSURE system is a key part of a broader vision for a holistic cardiac care ecosystem that supports patients and providers across the recovery journey. In addition to exhibiting, Kestra will also present new real-world clinical data highlighting the impact of the ASSURE system. Kestra is also proud to sponsor the Women in EP Luncheon for the fourth consecutive year--underscoring its ongoing commitment to leadership, innovation, and equity in cardiovascular care. Reported Earnings • Apr 16
Third quarter 2025 earnings released Third quarter 2025 results: US$1.25 loss per share. Net loss: US$24.8m (flat on 3Q 2024). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Announcement • Apr 15
Kestra Medical Technologies, Ltd. Provides Revenue Guidance for the Fiscal Year Ending April 30, 2025 Kestra Medical Technologies, Ltd. provided revenue guidance for the fiscal year ending April 30, 2025. For the period, the company expects revenue to be in the range of $58.0 million to $58.5 million, representing growth of approximately 109% to 110% compared to fiscal year 2024. Announcement • Apr 03
Kestra Medical Technologies, Ltd. to Report Q3, 2025 Results on Apr 14, 2025 Kestra Medical Technologies, Ltd. announced that they will report Q3, 2025 results on Apr 14, 2025 Board Change • Apr 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Maxwell Bikoff was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Mar 07
Kestra Medical Technologies, Ltd. has completed an IPO in the amount of $201.999984 million. Kestra Medical Technologies, Ltd. has completed an IPO in the amount of $201.999984 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 11,882,352
Price\Range: $17
Discount Per Security: $1.2104
Transaction Features: Reserved Share Offering; Sponsor Backed Offering Board Change • Mar 05
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Maxwell Bikoff was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 
